ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Avenue Therapeutics, Inc. ?
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 19.14% over the last 5 years
3
The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -1.09 MM
- RAW MATERIAL COST(Y) Fallen by 0% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -201.75 %
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 91.51%, its profits have risen by 76.4%
5
Majority shareholders : Mutual Funds
6
Market Beating Performance
- The stock has generated a return of 91.51% in the last 1 year, much higher than market (S&P 500) returns of 22.36%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Avenue Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Avenue Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Avenue Therapeutics, Inc.
91.51%
-0.39
217.13%
S&P 500
22.36%
1.70
13.18%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.14%
EBIT Growth (5y)
9.78%
EBIT to Interest (avg)
-7.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.37
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.19%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.26
EV to EBIT
0.71
EV to EBITDA
0.71
EV to Capital Employed
2.79
EV to Sales
-1.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
392.80%
ROE (Latest)
-107.03%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -1.09 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -201.75 %
PRE-TAX PROFIT(Q)
At USD -0.7 MM has Grown at 62.84%
NET PROFIT(Q)
At USD -0.7 MM has Grown at 62.72%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Avenue Therapeutics, Inc.
Operating Cash Flow
Highest at USD -1.09 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -0.7 MM has Grown at 62.84%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -0.7 MM has Grown at 62.72%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -201.75 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
